Challenging perceptions

As we settle in to the New Year Shire has already hit the headlines in a big way, thanks to its planned acquisition of Baxalta, a $32bn deal that it says will make it a global leader in rare diseases.However, with attention deficit hyperactivity disease (ADHD) treatment Vyvanse accounting for more than a quarter of its revenues it’s clear that, even after its combination with Baxalta is completed, neuroscience will remain high on the company’s agenda.Late last year, when the companies were still dancing around offers and conditions, I sat down with Shire’s Alvaro Herreros to talk about approaches to ADHD, working with patients and applying technology.Appointed international neuroscience portfolio strategy team lead last summer, Alvaro has responsibility for all of Shire’s neuroscience business, with the exception of the US,…


Link to Full Article: Challenging perceptions